New video discussion with Mesoblast CEO, page-90

The difference in market capital between MSB and CYP is largely due to the different stages that both companies are currently at:
- MSB has product on market, is about to launch a product in the US market and has multiple phase 3 trial readouts due by end of year and also has multiple licencing agreements with multiple pharmaceutical companies. MSB also has $180m cash on hand and
-CYP has no products on the market, only has one phase 3 trial which is yet to commence (currently on hold due to covid), and 3 products ready to enter phase 2 trials as well as an agreement with Fujifilm for $2.86m upon completion of planned phase 2 trial and a potential $43m in milestone and licencing payments. CYP has $13.6m cash on hand.

CYP has huge potential just like MSB, however has a long way to go before any commercialisation can begin. CYP represents a higher risk to investors due to phase 2 and 3 trials that are yet to begin and the longer path to commercialisation, probably at least 18 months before any potential product can be launched.